US EditionPublished • loading... • Updated
Understanding real-world microbiological outcomes will guide long-term CFTR modulator use in CF: GlobalData - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Understanding real-world microbiological outcomes will guide long-term CFTR modulator use in CF: GlobalData - Express Pharma
At the 2025 European Respiratory Society (ERS) International Congress in Amsterdam, researchers from Dalhousie University and the University of Toronto presented findings from a comprehensive, registry-based analysis examining the long-term clinical and microbiological impacts of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy. The study, spanning data from 2019-2023 across Canadian and US cystic fibrosis (CF) regist…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
